Akums receives Indian marketing approval for vonoprazan-based Helicobacter pylori combination kit
Akums has received Indian marketing approval for a fixed treatment kit combining vonoprazan, clarithromycin and amoxicillin for adults with Helicobacter pylori infection.
The 14-day regimen combines a potassium-competitive acid blocker with two antibiotics to support eradication of H. pylori, a major cause of peptic ulcer disease and an established gastric cancer risk factor.
The approval adds a new packaged treatment option in India for H. pylori eradication and may simplify delivery of guideline-based combination therapy.
Field | Content |
Alert Type | Approval |
Product | Vonoprazan, clarithromycin and amoxicillin combination kit |
Company | Akums Drugs & Pharmaceuticals |
Regulatory Authority | Indian regulatory authorities |
Approval Type | Marketing approval |
Indication | Treatment of Helicobacter pylori infection in adults |
Treatment Duration | 14 days |
Therapy Area(s) | Gastroenterology; infectious disease |
Technology or Modality | Fixed treatment kit combining potassium-competitive acid suppression and dual antibiotic therapy |
Active Ingredients | Vonoprazan; clarithromycin; amoxicillin |
Geography | India |
What Happened | Akums received marketing approval in India for a combination treatment kit containing vonoprazan, clarithromycin and amoxicillin for H. pylori infection. |
Why It Matters | The kit packages acid suppression and dual antibiotic therapy into a single treatment regimen, potentially simplifying H. pylori eradication therapy. |
Supporting Context | H. pylori infection is associated with peptic ulcer disease and increased risk of gastric malignancy, making effective eradication an important clinical objective. |
Key Takeaway | Akums has secured Indian marketing approval for a 14-day vonoprazan-based H. pylori eradication regimen. |
What to Watch | Commercial launch, pricing, prescribing uptake and comparative eradication rates versus proton-pump-inhibitor-based regimens. |
Primary Source | ETPharma.com |
Relevant Date | 22 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare